Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SBOT
CUSIPN/A
Phone805-488-2800
Debt
Debt-to-Equity RatioN/A
Current Ratio28.37
Quick Ratio27.80
Price-To-Earnings
Trailing P/E Ratio-0.39
Forward P/E Ratio-0.70
P/E GrowthN/A
Sales & Book Value
Annual Sales$230,000.00
Price / Sales19.31
Cash FlowN/A
Price / CashN/A
Book Value$4.92 per share
Price / Book0.27
Profitability
EPS (Most Recent Fiscal Year)($3.43)
Net Income$-5,030,000.00
Net Margins-3,187.58%
Return on Equity-67.28%
Return on Assets-63.30%
Miscellaneous
Employees28
Outstanding Shares3,290,000
Market Cap$4.68 million
Stellar Biotechnologies (NASDAQ:SBOT) Frequently Asked Questions
What is Stellar Biotechnologies' stock symbol?
Stellar Biotechnologies trades on the NASDAQ under the ticker symbol "SBOT."
When did Stellar Biotechnologies' stock split? How did Stellar Biotechnologies' stock split work?
Shares of Stellar Biotechnologies reverse split on Monday, May 7th 2018. The 1-7 reverse split was announced on Friday, April 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 4th 2018. An investor that had 100 shares of Stellar Biotechnologies stock prior to the reverse split would have 14 shares after the split.
How were Stellar Biotechnologies' earnings last quarter?
Stellar Biotechnologies Inc (NASDAQ:SBOT) issued its quarterly earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.07. The biotechnology company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.14 million. Stellar Biotechnologies had a negative return on equity of 67.28% and a negative net margin of 3,187.58%. View Stellar Biotechnologies' Earnings History.
When is Stellar Biotechnologies' next earnings date?
Who are some of Stellar Biotechnologies' key competitors?
Some companies that are related to Stellar Biotechnologies include Acasti Pharma (ACST), ESSA Pharma (EPIX), ERBA Diagnostics (ERBA), Diffusion Pharmaceuticals (DFFN), Bio-Path (BPTH), Kaya (KAYS), MusclePharm (MSLP), Wellness Center USA (WCUI), Midatech Pharma (MTP), Relmada Therapeutics (RLMD), Citius Pharmaceuticals (CTXR), Sonoma Pharmaceuticals (SNOA), Pulmatrix (PULM), IntelliPharmaCeutics Intl (IPCI) and THERAPIX BIOSCI/S (TRPX).
Who are Stellar Biotechnologies' key executives?
Stellar Biotechnologies' management team includes the folowing people:
- Mr. Frank R. Oakes, Chairman, Pres & CEO (Age 68)
- Ms. Kathi Niffenegger CPA, CFO & Corp. Sec. (Age 61)
- Dr. Gregory T. Baxter, Exec. VP of Corp. Devel. (Age 59)
- Mr. Gary Koppenjan, Sr. Director of Investor Relations & Communications
- Brando Lincicum, Exec. Director of Aquaculture and Facility Operations
Has Stellar Biotechnologies been receiving favorable news coverage?
News headlines about SBOT stock have been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Stellar Biotechnologies earned a coverage optimism score of 0.16 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 47.29 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Stellar Biotechnologies.
How do I buy shares of Stellar Biotechnologies?
Shares of SBOT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stellar Biotechnologies' stock price today?
One share of SBOT stock can currently be purchased for approximately $1.35.
How big of a company is Stellar Biotechnologies?
Stellar Biotechnologies has a market capitalization of $4.68 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-5,030,000.00 in net income (profit) each year or ($3.43) on an earnings per share basis. Stellar Biotechnologies employs 28 workers across the globe.
How can I contact Stellar Biotechnologies?
Stellar Biotechnologies' mailing address is 332 EAST SCOTT STREET, PORT HUENEME CA, 93041. The biotechnology company can be reached via phone at 805-488-2800 or via email at [email protected]
MarketBeat Community Rating for Stellar Biotechnologies (NASDAQ SBOT)
MarketBeat's community ratings are surveys of what our community members think about Stellar Biotechnologies and other stocks. Vote "Outperform" if you believe SBOT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBOT will underperform the S&P 500 over the long term. You may vote once every thirty days.
